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Abstract
Background: A variety of studies have evaluated the associations between polymorphisms in the promoter regions of
Matrix metalloproteinases (MMPs) and cancer metastasis. However, the results remain inconclusive. To better understand
the roles of MMP polymorphisms in metastasis, we conducted a comprehensive meta-analysis.
Methods: Electronic databases were searched (from January 2000 to June 2011) for any MMP genetic association studies in
metastasis. Overall and subgroup analyses were performed. Odds ratio (OR) and 95% confidence interval (CI) were used to
evaluate the associations between MMP polymorphisms and metastasis. Statistical analysis was performed with Review
Manager 5.0 and STATA11.0.
Results: Thirty-three studies addressing five MMP polymorphisms were analyzed among 10,516 cancer cases (4,059
metastasis-positive cases and 6,457 metastasis-negative cases). For MMP1 (21607)1G/2G, genotype 2G/2G increased the
overall risk of metastasis under the recessive model (OR=1.44, 95% CI=1.05–1.98). In subgroup analysis based on cancer
type, associations were found in head/neck and breast cancer under the recessive model, and also in breast cancer under
the dominant model. For MMP3 (21171) 5A/6A, the polymorphism decreased the overall risk of metastasis under two
genetic models (recessive: OR=0.80, 95%CI=0.64–0.99, dominant: OR=0.72, 95%CI=0.56–0.93). The polymorphisms of
MMP7 (2181) A/G and MMP9 (21562) C/T increased metastatic risk. However, no association was observed between MMP2
(21306) C/T and metastasis.
Conclusions: Our investigations demonstrate that polymorphisms in the promoter regions of MMP1, 3, 7 and 9 might be
associated with metastasis in some cancers. Further studies with large sample size for MMP2 should be conducted.
Citation: Liu D, Guo H, Li Y, Xu X, Yang K, et al. (2012) Association between Polymorphisms in the Promoter Regions of Matrix Metalloproteinases (MMPs) and
Risk of Cancer Metastasis: A Meta-Analysis. PLoS ONE 7(2): e31251. doi:10.1371/journal.pone.0031251
Editor: Chunyan He, Indiana University, United States of America
Received June 30, 2011; Accepted January 5, 2012; Published February 14, 2012
Copyright:  2012 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Natural Science Foundation of China (No. 30872549) and Natural Science Foundation Project of CQ CSTC
(2009BA5013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: baiyungene@gmail.com (YB); kangyang@mail.tmmu.edu.cn (KY)
. These authors contributed equally to this work.
Introduction
The lethal outcome of the vast majority of cancers is due to the
dissemination of metastatic tumor cells and the outgrowth of
secondary tumors at distant sites. Several steps occur in cancer
metastasis and invasion: dissociation of tumor cells at the primary
site, local invasion, angiogenesis, intravasation into the vasculature
or lymphatic systems, extravasation and proliferation at a distant
site [1]. Metastasis and invasion require the crossing of several
physical barriers such as the basement membrane or the adjacent
connective tissue.
Matrix metalloproteinases (MMPs) are a family of zinc-
dependent endopeptidases, which play critical roles in cancer
progression and metastasis [1–2]. Based on the structure and
substrate specificity, MMPs can be divided into five groups:
collagenases, gelatinases, stromelysins, matrilysins and membrane
MMPs [3]. MMPs are involved in normal physiological and
pathological processes such as degradation and remolding of
extracellular matrix, embryonic development, reproduction and
cancer [4–5]. MMPs are the main group of proteolytic enzymes
that are involved in cancer invasion and metastasis.
MMP1 and MMP3 are two important members in MMPs
family. They are neighbors located on 11q22 and play important
roles in cancer development and metastasis. MMP1 is one of the
widely expressed MMPs that can degrade type I, II and III
collagens. MMP3 is produced by connective tissue, which can
activate other MMPs and release cell surface molecules. It can
degrade numerous extracellular substrates, including collagens III
and IV [6]. MMP2 is able to degrade type IV collagen and some
bioactive molecules. Studies have shown that MMP2 is over-
expressed in head and neck squamous cell carcinoma tissues with
higher ability of invasion and metastasis [7]. MMP7 is a protease
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fibronectin, and type IV collagen. It is the smallest member of
MMP family and is over-expressed in many cancers. MMP9 is the
most complex member of MMP family. It has proteolytic activity
against type IV collagen, a major component of the basement
membrane. The expression of MMP9 is upregulated in various
human cancer types such as esophageal cancer, breast cancer and
gastric cancer.
A variety of molecular epidemiological studies have focused on
the associations between MMP polymorphisms and cancer
susceptibility. Some functional single nucleotide polymorphisms,
including MMP1 (21607)1G/2G (rs1799750), MMP2 (21306) C/
T (rs243865), MMP3 (21171) 5A/5A (rs3025058), MMP7 (2181)
A/G (rs11568818) and MMP9 (21562) C/T (rs3918242), have
been identified [8–12]. McColgan’s study [13] evaluated the
associations between polymorphisms of MMP1, 2, 3, 9 and
susceptibility to lung, breast and colorectal cancers. MMP
polymorphisms have been studied in cancer metastasis with
disparate results, partly due to the small number of subjects in
several studies. No meta-analysis has been conducted to reliably
evaluate these associations so far. To better clarify the associations
of these MMP polymorphisms with metastasis, we conducted a
comprehensive meta-analysis by collecting and analyzing the
published data.
Materials and Methods
Search strategy
Electronic databases of PubMed, ISI Web of Knowledge,
Medline, Embase and Google Scholar Search were used to
identify all published case-control studies that evaluate the
associations between MMP polymorphisms and metastasis (be-
tween January 2000 and June 2011). The Medical Subject
Headings and key words used for search were ‘‘metastasis’’, and
(‘‘MMPs’’ or ‘‘matrix metalloproteinase’’) and ‘‘polymorphism’’
and (‘‘cancer’’ or ‘‘neoplasm’’). The references of all identified
publications were hand-searched for additional studies. Authors
were contacted directly regarding crucial data not reported in
original articles. Abstracts, unpublished reports and articles written
in non-English languages were not included.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) independent case-
control design was used to evaluate the association between MMP
polymorphism and cancer in each study; (2) for each study, the
score of quality evaluation was over 6 (Table S1); (3) the number
or frequency of genotype was given in detail; (4) only genes with
two or more studies on one polymorphism were included in our
analysis.
The exclusion criteria were as follows: (1) studies with
insufficient information were excluded, for example, genotype
frequency or number not reported, or histopathological diagnosis
of cancer not confirmed; (2) if the same population was included in
previous studies, only the most recent or complete study was
included after careful examination.
To minimize the bias and improve the reliability, two
researchers extracted data with the inclusion and exclusion criteria
independently and reached a consensus.
Data extraction
Information such as the first author, publication year, country
origin, cancer type, ethnicity of study population, genotyping
method, number of metastasis-positive/negative cases and adjust-
ing factors was collected from each study. For studies including
subjects of different ethnicities, data were extracted separately and
categorized as Asians and Europeans (Caucasians). If one study
involved different cancer types, each cancer type was listed as a
separate study.
According to the TNM classification standardizations, cancer
patients were assigned to two subgroups named metastasis-positive
and metastasis-negative based on the presence/absence of
detectable lymph nodes or distant metastasis at the time of
diagnosis or follow-up.
Statistical analysis
Associations between MMP polymorphisms and metastasis were
evaluated by odds ratio (OR) and 95% confidence interval (CI). In
addition to overall comparison, we performed stratification
analysis based on cancer type (if one type contained less than
two individual studies, it was combined into the ‘other cancers’
group) and ethnicity of study population. Heterogeneity between
studies was assessed using Q test and p and I
2 value. I
2 was a value
that could describe the percentage of variation across studies,
where 0–25% indicated no observed heterogeneity and larger
values showed increasing heterogeneity, with 25–50% regarded as
low, 50–75% as moderate, and 75–100% as high. p.0.05 for the
Q-test indicated a lack of heterogeneity across studies, allowing to
use the fixed-effects model (the Mantel-Haenszel method) [14];
otherwise, the random-effects model was used (the DerSimonian
and Laird method) [15]. The heterogeneity was adjusted by
subgroup analysis and meta-regression. The pooled ORs were
performed on the dominant (BB+AB versus AA) and recessive
model (BB versus AB+AA) respectively (A represented major allele,
B represented minor allele). The significance of pooled ORs was
tested by Z test (p,0.05 was considered significant). The funnel
plot and Egger’s test were used to examine the publication bias
[16]. All p values were two-sided, and all statistical analyses were
performed using Review Manager 5.0 and STATA11.0 software.
To ensure reliability and accuracy of the results, two researchers
entered the data into the software program independently and
reached a consensus.
Results
Study characteristics
By the inclusion and exclusion criteria, 195 articles were found,
but only 48 studies were preliminarily identified for further
evaluation. After carefully evaluating the quality of the 48
remained articles, we excluded 15 studies, of which 1 study had
overlapped data and 14 studies did not report detailed genotype
data or genotype frequency information for metastasis-positive/
negative cases. Finally, 33 relevant studies [7,17–48] addressing
five polymorphisms in five MMP genes analyzed in 10,516 cancer
cases (4,059 metastasis-positive and 6,457 metastasis-negative
cases) were included (Flow diagram shown in Figure 1). The
study was judged to be of good quality if the total score was over 6,
otherwise, of poor quality. The total score of most studies was over
6 except for four studies [28–29,31,33] (Table S2). The
information of healthy controls was not provided in the four
studies. However, we only focused on the associations of MMP
polymorphisms with cancer metastasis, thus including the four
studies.
Information including cancer type, publication year, country,
ethnicity, genotyping method, genotype data, average age of cases
and controls, sample size (case/control), Hardy-Weinberg equi-
librium of controls, adjusting factors, determination of cancer and
metastasis positive or negative group was listed in Table 1 and
Table S3. There were 17 articles including 1,218 metastasis-
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1G/2G, 4 articles with 2,234 cancer cases for MMP2 (21306) C/
T, 8 articles with 2,367 cancer cases including 783 metastasis-
positive and 1,584 metastasis-negative cases for MMP3 (21171)
5A/6A, 3 articles with 808 cancer cases for MMP7 (2181) A/G
and 10 articles involving 2,552 cancer cases (1,129 metastasis-
positive and 1,423 metastasis-negative cases) for MMP9 (21562)
C/T.
Different genotyping methods were used in these studies,
including the classical polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) in 21 of 33 studies
[17–21,23,25–30,39,41–48], PCR-allele specific refractory muta-
tion system analysis (ARMS) in 2 studies [7,40], TaqMan assay
in 4 studies [19,22,34,37], PCR-sequencing in 6 studies
[24,31,33,35–36,38], and PCR – fluorescent fragment analysis in
2 studies [28,32].
Quantitative data synthesis
MMP1 (21607) 1G/2G. Seventeen studies investigating
MMP1 (21607) 1G/2G and its association with cancer metastasis
were identified [17–32,46]. There were significant associations in
overall comparison and subgroup analysis under the recessive
model. 2G/2G genotype increased the overall risk of metastasis
(OR=1.44, 95%CI=1.05–1.98, I
2=68%, p,0.01) (Figure 2).
Based on different cancer types, associations were also found in
head/neck cancer (OR=1.88, 95%CI=1.39–2.53, I
2=48%,
p=0.1) and breast cancer (OR=2.18, 95%CI=1.40–3.40, I
2=0,
p=0.9). However, nosignificant associationwas found incolorectal,
gastric and other cancers (including lung, cervical, esophageal
cancer and chondrosarcoma) (Table 2). Compared to 1G/1G
genotype, genotype 2G/2G or 1G/2G showed no association with
metastasis in overall analysis under the dominant model
(OR=1.24, 95%CI=0.81–1.90, I
2=49%, p=0.03). However,
individuals with genotype 2G/2G or 1G/2G had higher risk of
metastasis in breast cancer when stratified by cancer type
(OR=1.59, 95%CI=1.02–2.48, I
2=0%, p=0.69) (Table 2).
In the stratified analysis based on ethnicity of study population,
there was a strong association between metastasis and 1G/2G
polymorphism in European populations under recessive and
dominant models (dominant: OR=1.86, 95%CI=1.25–2.78;
recessive: OR=2.68, 95%CI=1.96–3.66). However, this associ-
ation was lost in Asian populations (Table 2).
MMP3 (21171) 5A/6A. Eight studies investigated MMP3
(21171) 5A/6A and its association with cancer metastasis
[28,30,33,36–40]. Individuals with genotype 5A/6A or 6A/6A
had lower risk of metastasis under the two genetic models
(dominant: OR=0.72, 95%CI=0.56–0.93; recessive: OR=0.80,
95%CI=0.64–0.99) (Figure 3). Stratified analysis by cancer type
showed that this association was found in breast cancer under the
dominant model (OR=0.56, 95%CI=0.39–0.79, I
2=0,p=0.53).
However, the association was lost under the recessive model.
In the stratified analysis by ethnicity, European individuals with
genotype 6A/6A or 5A/6A had lower risk of metastasis under the
dominant model (OR=0.76, 95%CI=0.58–0.99), whereas Asian
individuals with genotype 6A/6A had lower risk of metastasis
under the recessive model (OR=0.64, 95%CI=0.44–0.92)
(Table 2).
MMP9 (21562) C/T. Ten studies evaluated MMP 9(21562)
C/T polymorphism and its association with cancer metastasis
[20,25,28–29,34,41–44,48]. Genotype TT or CT increased the
overall risk of metastasis under the dominant model (OR=1.25,
95%CI=1.03–1.51, I
2=43%, p=0.07) (Figure 4). However, no
association was found between genotype TT and metastasis under
the recessive model. In stratified analysis by cancer type, there was
no significant association under the two genetic models. Based on
the ethnicity of study population, association was found in Asian
populations only under the dominant model (OR=1.37,
95%CI=1.02–1.83, I
2=5%, p=0.38), while no association was
found under the recessive model (Table 2).
MMP2 (21306) C/T and MMP7 (2181) A/G. Four studies
evaluated MMP2 (21306) C/T and its association with cancer
metastasis [7,33–35], and only three evaluated the association
between MMP7 (2181) A/G and metastasis [28,45,47]. For
MMP7 (2181), there was an association between GG genotype
and risk of metastasis under the recessive model (OR=2.43,
95%CI=1.25–4.73), however, no association was found under the
dominant model (Figure 5). Our analysis did not provide any
statistical evidence of association between MMP2 polymorphism
and risk of metastasis (Table 2).
Heterogeneity analysis
For MMP1 (21607)1G/2G, significant heterogeneity was found
in overall comparisons under the two genetic models (dominant:
I
2=49%, p=0.03; recessive: I
2=68%, p,0.01). The I
2 decreased
obviously and p value exceeded 0.05 after excluding the study of
Lai [32] under the dominant model (I
2=26%, p=0.20), indicating
that this study was the major source of heterogeneity. The
significance of pooled ORs and 95%CI under the dominant model
in both overall comparison and subgroup analysis was not
influenced by omitting Lai’s study. Heterogeneity under the
recessive model was still significant after excluding Lai’s study
(I
2=63%, p=0.0005), but it was eliminated after excluding four
studies [24,27,31–32] (I
2=44%, p=0.05). The significance of
pooled ORs under the recessive model was also not influenced by
omitting those four studies. In the present study, most genotype
data were based on the time of diagnosis except for the studies
Figure 1. Flow diagram of study identification.
doi:10.1371/journal.pone.0031251.g001
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Gene Cancer type Country Ethnicity Metastasis(+) Metastasis(2)
N AA AB BB N AA AB BB
MMP1 (21607) 1G/2G
Cao 2005 head/neck China Asian 67 27
a 40 29 14
a 15
Hashimoto 2004 head/neck Japan Asian 43 20
a 23 86 40
a 46
Kondo 2005 head/neck Japan/Taiwan Asian 40 6 34
b 43 4 39
b
Nasr 2007 head/neck Tunisia European 118 5 37 76 56 8 26 22
O-charoenrat 2006 head/neck Thailand Asian 181 75
a 106 119 76
a 43
Shimizu 2008 head/neck Japan Asian 19 9
a 10 50 23
a 27
Kouhkan 2008 colorectal Iran European 69 31
a 38 81 60
a 21
Ghilardi 2001 colorectal Italy European 17 6
a 11 43 31
a 12
Woo 2006 colorectal Korea Asian 79 2 23 54 106 5 31 70
Jin 2005 gastric China Asian 46 2 16 28 48 7 16 25
Matsumura 2004 gastric Japan Asian 89 11 42 36 126 15 46 65
Hughes 2007 breast London European 52 12 20 20 88 26 43 19
Przybylowska2006 breast Poland European 141 33 57 51 129 44 58 27
Fang 2005 NSCLC
c China Asian 123 13 41 69 74 8 24 42
Fong 2004 chondrosarcoma Taiwan Asian 14 6 8 0 53 12 26 15
Jin 2005 ESCC
d China Asian 59 6 24 29 72 12 29 31
Lai 2005 cervical Taiwan Asian 51 12 22 17 89 8 38 43
Albayrak 2007 prostate Turkey European 10 3 7
b 45 7 38
b
MMP2 (21306) C/T
Cotignola 2007 melanoma USA European 129 86 39 4 866 543 281 42
O-charoenrat 2006 head/neck Thailand Asian 152 140 12
b 87 66 21
b
Lei2007 breast Sweden European 230 121 86 23 559 317 203 39
Wu2007 gastric Taiwan Asian 93 83 7 3 118 88 26 4
MMP3 (21171) 5A/6A
Hughes 2007 breast London European 50 16 29 5 85 23 44 18
Ghilardi 2002 breast Italy European 40 15 25
b 46 9 37
b
Krippl 2004 breast Austria European 216 59 103 54 259 43 146 70
Fang 2005 NSCLC
c China Asian 123 7 41 75 73 0 17 56
Cotignola 2008 melanoma USA European 129 21 69 39 853 148 428 277
Tu 2007 head/neck Taiwan Asian 59 12
a 47 91 20
a 71
Zhang 2004 ESCC
d China Asian 59 1 26 32 72 0 20 52
Zhang 2004 GCA
e China Asian 46 2 11 33 48 1 12 35
Smolarz 2003 ovarian Poland European 61 17 24 20 57 20 22 15
MMP7 (2181) A/G
Hughes 2007 breast London European 49 17 20 12 81 30 39 12
Zhang 2005 ESCC
d China Asian 68 61 7
b 87 74 13
b
Zhang 2005 GCA
e China Asian 46 36 10
b 63 56 7
b
Zhang 2005 NSCLC
c China Asian 123 101 22
b 74 60 14
b
Wu 2011 cervical China Asian 39 17 14 8 178 96 70 12
MMP9 (21562) C/T
Nasr 2007 head/neck Tunisia European 118 96 20 2 56 43 12 1
Woo 2006 colorectal Korea Asian 79 67 11 1 106 88 17 1
Xing 2007 colorectal China Asian 46 29 17
b 87 71 16
b
Hughes 2007 breast London European 43 35 8
b 76 74 2
b
Przybylowska2006 breast Poland European 141 83 56 2 129 90 38 1
Lei 2007 breast Sweden European 230 164 61 5 555 392 143 20
Wang 2005 NSCLC
c China Asian 123 89 34
b 74 59 15
b
Matsumura 2005 gastric Japan Asian 63 44 16 3 114 89 22 3
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was performed by omitting the two studies. The overall result was
not influenced (OR=1.63, 95%CI=1.22–2.18).
The results of meta-regression for MMP1 (21607) 1G/2G
indicated that cancer site and ethnicity of study population
independently contributed to the heterogeneity observed under
dominant and recessive models (data not shown). Effects of cancer
type on heterogeneity were significant under dominant and recessive
models (dominant: p=0.084,0.1, recessive: p=0.047,0.1). Geno-
typing methods, sample size, and publication year were not
statistically associated with heterogeneity.
For MMP2 (21306) C/T, heterogeneity between studies was
statistically significant under the dominant model (I
2=83%,
p,0.01). The heterogeneity was eliminated after excluding two
studies [7,35] (I
2=44%, p=0.18). The significance of pooled ORs
and 95%CI was not influenced by omitting the two studies.
Genotype data of study [36] for MMP3 (21171) 5A/6A were
based on the time of follow-up. As selective bias for the result might
exist, we performed sensitivity analysis by omitting this study. The
significant association remained unchanged (OR=0.76, 95%CI=
0.58–0.99).
For MMP9 (21562) C/T, heterogeneity was statistically
significant in the subgroup analysis based on cancer type and
ethnicity of study population under the dominant model (Table 2).
The I
2 decreased and p value exceeded 0.05 after excluding the
study of Hughes [28], suggesting that this study was the major
source of heterogeneity. The significance of pooled ORs and
95%CI was not influenced by omitting Hughes’ study.
Publication bias analysis
Publication bias was assessed by performing funnel plot and
Egger’s regression test under the dominant and recessive models. If
the number of included studies was small, it is unnecessary to
perform publication bias analysis. After combining all the cancer
types, a little asymmetry was observed for MMP1 (21607)1G/2G,
but the results of Egger’s regression test suggested no evidence for
publication bias (dominant: t=20.63, p=0.54; recessive:
t=20.66, p=0.517). For MMP3 (21171) 5A/6A and MMP9
(21562) C/T, funnel plots were symmetrical and the Egger’s test
for both models showed no significance, suggesting little evidence
of publication bias.
Discussion
In our comprehensive meta-analysis, MMP1 (21607)1G/2G,
MMP7 (2181) A/G and MMP9 (21562) C/T were shown to
Gene Cancer type Country Ethnicity Metastasis(+) Metastasis(2)
N AA AB BB N AA AB BB
Awakura 2006 renal Japan Asian 154 106 48
b 25 20 5
b
Park 2011 colorectal Korea Asian 132 107 24 1 201 163 37 1
arepresents the number of AA+AB genotype,
brepresents the number of BB+AB genotype (A represents the major allele, B represents the minor allele),
cNSCLC represents non-small cell lung carcinoma,
dESCC represents esophageal squamous cell carcinoma.
eGCA represents gastric cardiac adenocarcinoma.
doi:10.1371/journal.pone.0031251.t001
Table 1. Cont.
Figure 2. Forest plot of cancer metastasis risk associated with MMP1 (21607) 1G.2G under the recessive model. A random-effects
model was used. The squares and horizontal line represent the study-specific OR and 95% CI. The diamond represents the pooled results of OR and
95% CI.
doi:10.1371/journal.pone.0031251.g002
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5A/6A was protective in metastasis. Meanwhile, there was no
association between MMP2 (21306) C/T and metastasis.
MMP1 is implicated in cancer susceptibility and metastasis in a
variety of cancers. A single nucleotide polymorphism at 21607 bp
in the MMP1 promoter is described in Rutter’s study [8]. This
promoter region is characterized by a 1G/2G polymorphism,
where 2G allele creates an Ets-binding site and increases the
transcriptional activity compared to 1G allele. In our analysis, 2G/
2G genotype increased the risk of metastasis under the recessive
model, whereas no association was found in the dominant model.
The result demonstrates that homozygous 2G has a stronger effect
on an individual’s phenotype than heterozygous 2G. Therefore,
individuals with 2G/2G genotype have a higher risk of metastasis
than those with 1G/2G genotype. When stratified by cancer types,
this association was found in head/neck cancer and breast cancer
under the recessive model. Results for different cancer types were
inconsistent, which might be caused by the different microenvi-
ronments and mechanisms in different cancer types. When we
conducted a subgroup analysis based on ethnicity, significant
Table 2. Stratified analysis of MMP polymorphisms on cancer metastasis.
Variables N
a Dominant genetic model N
a Recessive genetic model
OR(95%CI) I
2 P
b OR(95%CI) I
2 P
b
MMP1 21607
Tumor site
head/neck 2
19–20 1.53
c(0.24–9.53) 76 0.04 5
17–18,20–22 1.88(1.39–2.53) 48 0.1
colorectal 1
25 1.91(0.36–10.09) — — 3
23–25 2.45
c(0.98–6.12) 75 0.02
gastric 2
26–27 1.33(0.65–2.74) 54 0.14 2
26–27 0.82(0.52–1.29) 61 0.11
breast 2
28–29 1.59(1.02–2.48) 0 0.69 2
28–29 2.18(1.40–3.40) 0 0.9
other 5
26,30–32.46 0.89
c(0.39–2.04) 62 0.03 4
26,30–32 0.81(0.56–1.17) 47 0.13
Ethnicity
Asian 7
19,25–27,30–32 0.90(0.62–1.32) 41 0.1 10
17–18,21–22,25–27,30–32 1.06
c(0.76–1.48) 57 0.01
European 4
20,28–29,46 1.86(1.25–2.78) 0 0.42 5
20,23–24,28–29 2.68(1.96–3.66) 0 0.68
Total 11 1.24
c(0.81–1.90) 49 0.03 15 1.44
c(1.05–1.98) 68 ,0.0001
MMP2 21306
Tumor site
All 4
7,33–35 0.61
c(0.33–1.12) 83 0.0005 3
33–35 1.17(0.75–1.83) 8 0.34
Ethnicity
Asian 2
7,35 0.31(0.18–0.54) 0 0.63 1
35 0.95(0.21–4.35) — —
European 2
33–34 1.03(0.81–1.32) 44 0.18 2
33–34 1.19(0.75–1.90) 52 0.15
MMP3 21171
Tumor site
breast 3
28,36–37 0.56(0.39–0.79) 0 0.53 2
28,37 0.80(0.55–1.17) 44 0.18
other 4
30,33,39–40 0.99(0.67–1.46) 5 0.38 5
30,33,38–40 0.80(0.62–1.03) 34 0.18
Ethnicity
Asian 2
30,39 0.21(0.04–1.02) 0 0.72 3
30,38–39 0.64(0.44–0.92) 27 0.25
European 5
28,33,36–37,40 0.76(0.58–0.99) 52 0.08 4
28,33,37,40 0.89(0.69–1.16) 4 0.37
Total 7 0.72(0.56–0.93) 35 0.15 7 0.80(0.64–0.99) 25 0.23
MMP7 2181
Total 3
28,45,47 1.17(0.81–1.67) 0 0.45 2
28,47 2.43(1.25–4.73) 0 0.33
MMP9 21562
Tumor site
colorectal 3
25,41,48 1.07(0.81–1.38) 43 0.15 2
25,48 1.43(0.26–10.26) 0 0.95
breast 3
28–29,34 1.23
c(0.94–1.61) 77 0.01 2
29,34 0.70(0.29–1.70) 0 0.4
other 4
20,42–44 1.32(0.90–1.94) 0 0.45 2
20,43 0.89(0.44–1.80) 0 0.76
Ethnicity
Asian 6
25,41–44,48 1.37(1.02–1.83) 5 0.38 3
25,43,48 1.66(0.47–5.84) 0 0.98
European 4
20,28–29,34 1.33
c(0.74–2.36) 69 0.02 3
20,29,34 0.72(0.31–1.65) 0 0.68
Total 10 1.25(1.03–1.51) 43 0.07 6 0.92(0.47–1.82) 0 0.85
aNumber of comparisons.
bP value for Q test.
cRandom effect model was used.
doi:10.1371/journal.pone.0031251.t002
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the two genetic models. In our analysis, populations selected in the
two studies on breast cancer were all European, which might cause
selection bias. Therefore, we could not conclude that European
populations with this polymorphism have a higher risk of
metastasis than Asian populations.
The promoter region of MMP3 gene contains an adenosine
insertion/deletion polymorphism located at 21171 bp relative to
the transcriptional start site, where one allele has five adenosines
and the other has six adenosines. It is implicated that the
transcriptional activity of MMP3 in individuals with a 5A allele is
twice that in individuals with a 6A allele [9]. In overall
comparison, 5A/6A polymorphism had a protective role in
metastasis under the two genetic models. The result in dominant
model was more evident than that in recessive model, and it was
demonstrated that the heterozygous 6A had a stronger effect on an
individual’s phenotype than homozygous 6A. Therefore, individ-
uals with 5A/6A genotype had an apparent protective role in
metastasis compared to those with 6A/6A genotype. When
stratified by cancer type, this protective role was only found in
breast cancer under dominant model. As mentioned above, this
result may be caused by different microenvironments in different
cancers. In the subgroup analysis, 5A/6A polymorphism decreased
the risk of metastasis in European populations under dominant
model, and this protective role was found in Asian populations
under recessive model. As the populations in the three studies on
breast cancer were all European, selection bias may exist and the
final result may be influenced. The association between ethnicity
and metastasis remains uncertain, waiting to be analyzed by
further studies using larger sample size.
MMP9 is the most complex member of MMPs, which plays an
important role in metastasis. The C to T substitution in the
promoter region of MMP9 gene has a higher transcriptional
activity of the T-allelic promoter, which might be caused by DNA-
protein interaction abolishment by the C to T substitution at this
polymorphism site [10]. Significant association between this
polymorphism and metastasis was only found in dominant model.
This result shows that individuals with CT genotype have a higher
risk of metastasis than those with TT genotype. When analyzed
based on ethnicity of study population, Asian populations with
genotype TT or CT had a higher risk of metastasis, in contrast, no
association was found in European populations. This result
demonstrates that Asian populations with this polymorphism
might be susceptible to metastasis compared to Europeans under
dominant model. In our analysis, no significant heterogeneity was
found in overall comparisons under the two genetic models.
An A to G transition at 2181 base pair position upstream of
the transcription start site of MMP7 gene has been reported. The
G allele has greater basal transcriptional activity than A allele in
vitro experiment [12]. Our results demonstrate that individuals
with GG genotype could increase the risk of metastasis, and this
result is consistent with the above hypothesis. The promoter
region of MMP2 has been shown to contain several cis-acting
regulatory elements, and a 21306 C to T transition interrupts
Sp1-binding site and diminishes the promoter activity [11]. For
MMP2 (21306) C/T, no statistical association and significant
Figure 3. Forest plot of cancer metastasis risk associated with MMP3 (21171) 5A.6A. A fixed-effects model was used. A indicates the result
under the dominant model (6A/6A+5A/6A vs. 5A/5A). B indicates the result under the recessive model (6A/6A vs. 5A/5A+5A/6A). The squares and
horizontal line represent the study-specific OR and 95% CI. The diamond represents the pooled results of OR and 95% CI.
doi:10.1371/journal.pone.0031251.g003
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subgroup analysis. Because there are only four studies for
MMP2, the negative results do not mean that there was no
association with metastasis.
Results for different MMP polymorphisms in metastasis are
inconsistent, which can be explained by several reasons. First, the
study population in each report comes from different areas and
races. Different genetic backgrounds and environmental factors
could influence the results. Second, the small sample size in some
studies might influence the overall effect. It is necessary to gather
studies with larger sample sizes to decrease the possibility of false
positive and negative. Third, different MMP regulation mecha-
Figure 5. Forest plot of cancer metastasis risk associated with MMP7 (2181) A.G. A fixed-effects model was used. A indicates the result
under the dominant model (GG+AG vs. AA). B indicates the result under the recessive model (GG vs. AG+AA). The squares and horizontal line represent
the study-specific OR and 95% CI. The diamond represents the pooled results of OR and 95% CI.
doi:10.1371/journal.pone.0031251.g005
Figure 4. Forest plot of cancer metastasis risk associated with MMP9 (21562) C.T under the dominant model. A fixed-effects model was
used. The squares and horizontal line represent the study-specific OR and 95% CI. The diamond represents the pooled results of OR and 95% CI.
doi:10.1371/journal.pone.0031251.g004
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why MMP polymorphisms play different roles in cancer
metastasis. Fourth, some cases are gynaecological cancers. The
development and metastasis of gynaecological cancers could be
influenced by some environmental factors and other factors
including oestrogen, pregnancy and coitus.
Heterogeneity is an important problem when interpreting the
results of our meta-analysis. In this study, significant heterogeneity
was found in three of the five polymorphisms. For these
polymorphisms, the heterogeneity disappeared after excluding
several studies. Results of meta-regression demonstrate that cancer
type and ethnicity of the studied population are the major source
of the heterogeneity. Because the genotype data of studies [21–
22,36] were based on the time of follow-up, sensitivity analysis was
done by omitting these three studies, and the results were not
influenced by omitting them. Therefore, the three studies were
included in our studies.
There are some limitations in our analysis. First, although we
collected all the eligible studies, the sample size of the included
studies was not large enough, which could increase the likehood of
type I and type II errors. Therefore, there was a lack of statistical
power to better evaluate the association between MMP polymor-
phisms and metastasis, especially in subgroup analysis. Second, we
showed the results by combining all cancers, however, the results
in subgroup analysis were more meaningful. We only analyzed the
data based on different cancer types and ethnicity of the studied
population due to the limited data. Third, gene-gene and gene-
environment interactions were not analyzed. It is possible that
specific environmental and lifestyle factors may alter those
associations between gene polymorphisms and metastasis. There-
fore, it is necessary to evaluate the roles of some special
environment factors and lifestyles such as diet, alcohol consump-
tion and smoking status in metastasis. Fourth, although the funnel
plot and Egger’s test did not show any publication bias, the
influence of bias in the present analysis could not be completely
excluded. For example, studies with positive results are more easily
published than those with negative results, and only studies
published in English are included. Finally, as we only focused on
the associations of MMP polymorphisms with cancer metastasis in
the present study, the significance was limited. To ensure the
validity and reliability of the conclusions, it is important to perform
a meta-analysis on the associations between metastasis positive
cases vs. healthy controls and negative cases vs. healthy controls in
the future study.
In conclusion, the results in our meta-analysis demonstrate that
the polymorphisms of MMP1, 3, 7 and 9 have significant
associations with the risk of metastasis, although some results are
limited by the small number of studies. However, no significant
association exists between MMP2 (21306) C/T and metastasis.
This polymorphism may not be the major risk of metastasis.
Further studies with large sample size are needed to evaluate its
association with metastasis.
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